Semaglutide Semaglutide was designed as a potent, long-acting GLP-1 analogue that could be administered subcutaneously (s.c.) once weekly, rather than s.c
The litigation has produced zero settlements so far
It is worth noting that GLP-1 receptor agonists show neutral effects on heart failure hospitalisation, unlike SGLT2 inhibitors which demonstrate benefit in this area
It becomes part of their morning ritual, like taking vitamins
Standard listed program pricing starts at $159 per month for compounded semaglutide and $279 per month for compounded tirzepatide
These five biotech companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline builders that could diversify a metabolic-focused acquirer's portfolio into oncology, immunology, and neuroscience